Strategy

An answer to your question: What does the Part D coverage gap do to drug sales?

Glaxo launched a YouTube page targeting potential employees through YouTube. One video in particular features CEO Andrew Witty talking about his adventures in GSK. Is this the future of recruitment?

A new global CEO study examines what near- and long-term changes pharma leaders expect to face and in what areas they are planning to focus their attention. Key focus areas: global business design and new markets.

A look at some of the court cases that could actually change the pharma playing field

Could gene silencing be the next great innovation in drug development? Some biotechs are betting on it.

Merck bolsters vaccine making division with the addition of 400 new employees to fill its new manufacturing plant.

French drugmaker to cut 800 jobs, joining the long list of companies restructuring to make ends meet.

In our first ever Emerging Leadership Awards, we profile 45 talented young professionals who will lead pharma into the next generation

An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner

Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.

In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates

How do you find and license the best drugs out there? If you're Merck, you send scientists to go get 'em

Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work

Meet the Korean pharma consumer: affluent, aging, and crazy about drugs

One company's program provides an interesting model for the future of DTP

San Diego's booming biotech cluster searches for its future-and yours

Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging.

Bill Gates and Co. officially released Office for Business Applications (OBA) for the life sciences industry. This set of tools allows software developers to build applications that seamlessly connect back-end enterprise systems with MS Office programs.

With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

Here's the saga of how market research, health outcomes, and dozens of other tools that connect the industry to patients came to be.

...and other ways you never thought to sell your drugs

The contamination of heparin in China cast the drugmaker, its US supplier, and FDA as indifferent and incompetent. Then the story took a very strange turn...

A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

A review of a pilot ePrescribing program reveals that if physicians are given the proper support, the technology can increase safer prescribing habits and boost compliance.

Pharma gets less ink as news reporters shift their sights to other topics? That's a good thing--Isn't it?

Roche has always gone its own way with biologics, deals, and new medicines. Now that the rest of industry has caught on, how can Roche stay ahead of its time?